These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 3106585)

  • 1. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical overview of mesna.
    Burkert H
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
    Luce JK; Simons JA
    Med Pediatr Oncol; 1988; 16(6):372-4. PubMed ID: 3143903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
    Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD; Munshi N; Einhorn LH; Loehrer PJ
    Cancer Invest; 1990; 8(2):269. PubMed ID: 2119246
    [No Abstract]   [Full Text] [Related]  

  • 7. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C; Steiner R; Viollier AF
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z; Utracka-Hutka B
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W; Klein HO; Brock N; Burkert H; Günther U; Hoefer-Janker H; Mitrenga D; Schnitker J; Voigtmann R
    Cancer Treat Rep; 1979 Mar; 63(3):501-5. PubMed ID: 106965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
    Matz EL; Hsieh MH
    Urology; 2017 Feb; 100():16-19. PubMed ID: 27566144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of mesna with ifosfamide.
    Goren MP
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N
    Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
    Hows JM; Mehta A; Ward L; Woods K; Perez R; Gordon MY; Gordon-Smith EC
    Br J Cancer; 1984 Dec; 50(6):753-6. PubMed ID: 6437430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
    Ehrlich RM; Freedman A; Goldsobel AB; Stiehm ER
    J Urol; 1984 May; 131(5):960-2. PubMed ID: 6423841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the benefits of sodium 2-mercaptoethane sulfonate (MESNA) therapy for children undergoing high-dose chemotherapy].
    Sato J; Takaue Y; Saito S; Okamoto Y; Hirao A; Shimizu T; Abe T; Watanabe T; Kawano Y; Ninomiya T
    Rinsho Ketsueki; 1993 Jan; 34(1):7-12. PubMed ID: 8450612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
    Korkmaz A; Oter S; Deveci S; Goksoy C; Bilgic H
    J Urol; 2001 Sep; 166(3):1119-23. PubMed ID: 11490309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
    Antman KH; Ryan L; Elias A; Sherman D; Grier HE
    J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National survey of use of mesna for the prevention of cyclophosphamide-induced hemorrhagic cystitis in recipients of bone marrow transplants.
    Nicolau DP; Hogan KR
    Mayo Clin Proc; 1992 Jun; 67(6):611-2. PubMed ID: 1434892
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
    Case DC; Anderson J; Ervin TJ; Gottlieb A
    Med Pediatr Oncol; 1988; 16(3):182-6. PubMed ID: 3132591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
    Shepherd JD; Pringle LE; Barnett MJ; Klingemann HG; Reece DE; Phillips GL
    J Clin Oncol; 1991 Nov; 9(11):2016-20. PubMed ID: 1941060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.